Toxicity and costs of cancer treatment reduced by deferring CDK4/6 inhibitor use
Nature – No difference in survival outcomes between use of CDK4/6 inhibitors as first- or second-line treatment in metastatic breast cancer.
Related Articles
Three decades of protein-fragment complementation
Nature Reviews Molecular Cell Biology – Stephen Michnick provides a brief history of protein-fragment complementation — an approach to studying protein–protein interactions in living…
CRIPTO’s multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data
Oncogene – CRIPTO’s multifaceted role in driving aggressive prostate cancer unveiled by in vivo, organoid, and patient data
How proteins sense their cellular environment
Nature Reviews Molecular Cell Biology – In this Comment article, Monika Fuxreiter discusses possible roles of dynamic, fuzzy protein interactions and their importance in changing…
Medical School Food Pantry Donations | New York Chapter of the American College of Physicians
This region represents members in NYACP Districts of Manhattan and the Bronx.
Accuracy of DOTATATE PET imaging in the preoperative planning of small bowel neuroendocrine tumor resection
Background and Objectives We assessed the accuracy of preoperative gallium-68 DOTA-Tyr3-octreotate (DOTATATE) positron emission tomography (PET) imaging in estimating multifocality and nodal metasta…
Welcome! You are invited to join a webinar: IACH Webinar -Blood Diseases in the ICU. After registering, you will receive a confirmation email about joining the webinar.
Speaker: Elie Azoulay Designation: Professor in intensive care medicine Editor in Chief of Intensive Care Medicine 2012-2018 ESICM President 2022-2024 Affiliation: University Paris Cité, Saint-Louis…
Genomic Alterations in DNA Mismatch Repair Genes Across Different Cancer Types | JCO Precision Oncology
PURPOSEPD-1 inhibition is effective in patients with mismatch repair deficient (dMMR) solid tumors in a tumor-agnostic fashion. However, dMMR testing by immunohistochemistry (IHC) is not…
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial
Although this study did not meet the primary endpoint, activity and safety profiles of primary lung tumour SBRT followed by concurrent mediastinal chemoradiotherapy were favourable…
Pedal Through Iceland for a Cause: Join the IMF’s Fight Against Multiple Myeloma
A team of 15 determined individuals, including multiple myeloma cancer survivors, care partners, and world-renowned physicians, embark on the Iceland Cycling…
